612 related articles for article (PubMed ID: 7707396)
21. Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models.
Watanabe T; Nakayama Y; Naito M; Oh-hara T; Itoh Y; Tsuruo T
Anticancer Drugs; 1996 Nov; 7(8):825-32. PubMed ID: 8991185
[TBL] [Abstract][Full Text] [Related]
22. Combined therapy with anti-P-glycoprotein antibody and macrophage colony-stimulating factor gene transduction for multiorgan metastases of multidrug-resistant human small cell lung cancer in NK cell-depleted SCID mice.
Yano S; Hanibuchi M; Nishioka Y; Nokihara H; Nishimura N; Tsuruo T; Sone S
Int J Cancer; 1999 Jul; 82(1):105-11. PubMed ID: 10360828
[TBL] [Abstract][Full Text] [Related]
23. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells.
Kitazono M; Sumizawa T; Takebayashi Y; Chen ZS; Furukawa T; Nagayama S; Tani A; Takao S; Aikou T; Akiyama S
J Natl Cancer Inst; 1999 Oct; 91(19):1647-53. PubMed ID: 10511592
[TBL] [Abstract][Full Text] [Related]
26. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
27. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.
De Vincenzo R; Scambia G; Benedetti Panici P; Fattorossi A; Bonanno G; Ferlini C; Isola G; Pernisco S; Mancuso S
Int J Cancer; 1996 Nov; 68(3):340-8. PubMed ID: 8903476
[TBL] [Abstract][Full Text] [Related]
28. Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism.
Bergman PJ; Gravitt KR; Ward NE; Beltran P; Gupta KP; O'Brian CA
Invest New Drugs; 1997; 15(4):311-8. PubMed ID: 9547673
[TBL] [Abstract][Full Text] [Related]
29. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway.
Jiang L; Wang P; Sun YJ; Wu YJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):265. PubMed ID: 31215501
[TBL] [Abstract][Full Text] [Related]
30. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.
Uchiyama-Kokubu N; Watanabe T
Anticancer Drugs; 2001 Oct; 12(9):769-79. PubMed ID: 11593059
[TBL] [Abstract][Full Text] [Related]
31. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
32. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
[TBL] [Abstract][Full Text] [Related]
33. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.
Jin J; Sun H; Wei H; Liu G
Invest New Drugs; 2007 Apr; 25(2):95-105. PubMed ID: 16937080
[TBL] [Abstract][Full Text] [Related]
34. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein.
Vanhoefer U; Cao S; Minderman H; Tóth K; Scheper RJ; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Feb; 2(2):369-77. PubMed ID: 9816180
[TBL] [Abstract][Full Text] [Related]
35. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
Gridley DS; Slater JM; Stickney DR
J Biol Response Mod; 1989 Dec; 8(6):593-602. PubMed ID: 2513378
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the antitumor activity of recombinant human gamma-interferon employing human melanoma xenografts in athymic nude mice.
Trotta PP; Harrison SD
Cancer Res; 1987 Oct; 47(20):5347-53. PubMed ID: 3115565
[TBL] [Abstract][Full Text] [Related]
37. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
Germann UA; Shlyakhter D; Mason VS; Zelle RE; Duffy JP; Galullo V; Armistead DM; Saunders JO; Boger J; Harding MW
Anticancer Drugs; 1997 Feb; 8(2):125-40. PubMed ID: 9073309
[TBL] [Abstract][Full Text] [Related]
38. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
39. Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype.
Frank MH; Pomer S
J Cancer Res Clin Oncol; 1999; 125(2):117-20. PubMed ID: 10190320
[TBL] [Abstract][Full Text] [Related]
40. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
